Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy

Mersana Therapeutics Inc(NASDAQ:MRSN) announced a global collaboration that providesGSK plc(NYSE:GSK) an exclusive option to co-develop and commercialize XMT-2056.

Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.

Mersana has retained options to profit-share and to co...